SCHEMBL20647783

SCHEMBL20647783

O=S(=O)(c1cc(C(O)Nc2ccc(F)c(Cl)c2)ccc1F)N1CC(O)CCC(F)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.39
▸ TP53 P04637 5/20 0.38
▸ THRB P10828 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33
▸ DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20647804 0.88 MAPT (0.39) MAPTTP53THRBSMN1; SMN2CYP3A4
SCHEMBL20647781 0.87 CYP3A4 (0.42) MAPTTP53THRBSMN1; SMN2CYP3A4
SCHEMBL20083954 0.86 MAPT (0.41) MAPTTP53THRBSMN1; SMN2LMNA
SCHEMBL20647810 0.82 CYP3A4 (0.41) MAPTTP53SMN1; SMN2CYP3A4CYP2D6
SCHEMBL16903209 0.80 MAPT (0.56) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL20647758 0.80 MAPT (0.39) MAPTTP53THRBSMN1; SMN2CYP3A4
SCHEMBL20647806 0.79 MAPT (0.45) MAPTTP53THRBSMN1; SMN2LMNA
SCHEMBL20647827 0.76 MAPT (0.44) MAPTTP53THRBSMN1; SMN2CYP3A4
SCHEMBL20647809 0.76 CYP3A4 (0.41) MAPTTP53CYP3A4CYP2D6CYP2C9
SCHEMBL21844846 0.75 MDM2 (0.42) MAPTSMN1; SMN2LMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392349-B2 Azepane derivatives and methods of treating hepatitis B infections NOVIRA THERAPEUTICS, INC. (US) 2019-08-27 — — US disclosed
US-20190016682-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS NOVIRA THERAPEUTICS, INC. 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016682-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HDGF, AZI2 MAPT 4757/4885TP53 1049/4885THRB 1328/4885
US-10392349-B2 Azepane derivatives and methods of treating hepatitis B infections HAVCR2, HDGF, AZI2 MAPT 4757/4885TP53 1049/4885THRB 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback